Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial

The goal of this randomized, blinded, crossover clinical trial was to determine whether Nuedexta (dextromethorphan and quinidine) enhanced speech, swallowing, and salivation in patients with ALS. Sixty patients with amyotrophic lateral sclerosis (ALS) received either Nuedexta or placebo for 28 to 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Richard, Pioro, Erik, Myers, Kathleen, Sirdofsky, Michael, Goslin, Kimberly, Meekins, Gregg, Yu, Hong, Wymer, James, Cudkowicz, Merit, Macklin, Eric A., Schoenfeld, David, Pattee, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509619/
https://www.ncbi.nlm.nih.gov/pubmed/28070747
http://dx.doi.org/10.1007/s13311-016-0508-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509619/
https://www.ncbi.nlm.nih.gov/pubmed/28070747
http://dx.doi.org/10.1007/s13311-016-0508-5

Ejemplares similares